Market Place
Sourcing Support
Soleno to Attend Piper Sandler 36th Annual Health Conference
27 Nov 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Announces FDA Review Extension for DCCR Tablets
26 Nov 2024 //
GLOBENEWSWIRE
Soleno Presents Diazoxide Choline in Prader-Willi Syndrome
14 Nov 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Reports Q3 2024 Financials & Updates
06 Nov 2024 //
GLOBENEWSWIRE
Soleno Therapeutics to Attend November Investor Conferences
28 Oct 2024 //
#N/A
Soleno Therapeutics Announces Passing Of Former Chairman Ernest Mario
21 Oct 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Announces DCCR Regulatory Update
08 Oct 2024 //
GLOBENEWSWIRE
Soleno Therapeutics To Present At Cantor Healthcare Conference
16 Sep 2024 //
GLOBENEWSWIRE
Soleno Therapeutics` NDA For DCCR Accepted With Priority Review By FDA
27 Aug 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Rule
19 Aug 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Updates to its Board of Directors
15 Aug 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Provides Corporate Update And Q2 2024 Results
07 Aug 2024 //
GLOBENEWSWIRE
Soleno Submits New Drug Application To FDA For DCCR To Treat Willi Syndrome
28 Jun 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
24 Jun 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Set to Join Russell 3000® Index
04 Jun 2024 //
GLOBENEWSWIRE
Soleno Therapeutics to Participate in Upcoming Investor Conferences
22 May 2024 //
GLOBENEWSWIRE
Soleno Announces DCCR Prader-Willi Data At ENDO 2024
22 May 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
15 May 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Q1 2024 Results And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
02 May 2024 //
GLOBENEWSWIRE
Soleno Prices ~$138M Public Offering Of Common Stock
02 May 2024 //
GLOBENEWSWIRE
Soleno DCCR vs PWS Natural History Data Published
30 Apr 2024 //
GLOBENEWSWIRE
Soleno`s DCCR Gets FDA Breakthrough Designation in PWS
29 Apr 2024 //
GLOBENEWSWIRE
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Apr 2024 //
GLOBENEWSWIRE
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
Soleno Therapeutics to Present at TD Cowen 44th Annual Health Care Conference
22 Feb 2024 //
GLOBENEWSWIRE
Soleno Therapeutics to Present at Upcoming February Investor Conferences
01 Feb 2024 //
GLOBENEWSWIRE
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Jan 2024 //
GLOBENEWSWIRE
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
24 Jan 2024 //
GLOBENEWSWIRE
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
GLOBENEWSWIRE
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Nov 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Peer-Reviewed Publication of Results fromDCCR
06 Nov 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Announces DCCR Data Presentation
04 Oct 2023 //
GLOBENEWSWIRE
Soleno Announces DCCR Data Presentation at the Prader-Willi Research Symposium
04 Oct 2023 //
GLOBENEWSWIRE
Soleno Announces Closing of Underwritten Public Offering of Common Stock
02 Oct 2023 //
GLOBENEWSWIRE
Soleno Announces Pricing of Approx $120 Million Underwritten Public Offering
28 Sep 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
27 Sep 2023 //
GLOBENEWSWIRE
Soleno Announces Positive Results from Study C602 of DCCR
26 Sep 2023 //
GLOBENEWSWIRE
Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
25 Sep 2023 //
GLOBENEWSWIRE
Soleno Announces Appointment of Matthew Pauls to Board of Directors
16 Aug 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Provides Corporate Update and Reports1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Soleno Completes Enrollment, Withdrawal Period of Study C602 of DCCR
03 May 2023 //
GLOBENEWSWIRE
Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks
28 Mar 2023 //
GLOBENEWSWIRE
Soleno Reports Fourth Quarter and Full-Year 2022 Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
Soleno to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
Soleno Announces Publication of Results from Completed Phase 3 Trial of DCCR
26 Jan 2023 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
19 Dec 2022 //
GLOBENEWSWIRE
Soleno Therapeutics Provides Corporate Update &Reports 3Q 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
Soleno Therapeutics to Participate in the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Soleno Therapeutics Provides Corporate Update and Reports Q2 Financial Results
10 Aug 2022 //
GLOBENEWSWIRE
Soleno Tx Provides Regulatory Update on DCCR for Prader-Willi Syndrome
20 Jul 2022 //
GLOBENEWSWIRE
Soleno Tx Announces Presentation of DCCR Data at IPSO Conference
11 Jul 2022 //
GLOBENEWSWIRE
Soleno Presents Positive Long-Term Data for Prader-Willi Syndrome Treatment
15 Jun 2022 //
TRIALSITENEWS
Soleno Tx Presents Long Term Data for DCCR Showing Improvements
13 Jun 2022 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Presentations at ENDO 2022
07 Jun 2022 //
GLOBENEWSWIRE
Soleno Therapeutics Announces Presentations at the 2022 ECE
19 May 2022 //
GLOBENEWSWIRE
Soleno Therapeutics to Participate in the H.C. Wainwright Conference
17 May 2022 //
GLOBENEWSWIRE
